MANE — Veradermics, Inc

—
NYSE · Health Care · Pharmaceuticals · CIK 1827635 ·
Last close
$124.39
Market Cap
$5.25B
52W High
$156.63
52W Low
$32.00
ADV30
700,058
Next earnings
2026-11-10
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -29,553,000 -23,502,000 825,735,000 319,333,000 12,122,000
Mar 2026 0 — -29,713,000 -27,232,000 397,356,000 168,412,000 6,716,000
Dec 2025 0 — -22,753,000 -21,847,000 152,619,000 21,766,000 273,633,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-78,300,000
Investing CF
$-473,364,000
Financing CF
$862,401,000
CapEx
$-24,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.00
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-174,155,000
Inventory
—
Receivables
$1,589,000
ST Investments
$500,561,000
EBIT TTM
$-100,273,000
Pretax Income TTM
$-92,684,000
Interest Exp TTM
$0
Analysts
6

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -71,557,000 -69,995,000 152,619,000 273,633,000 -121,014,000 -71,602,000
Dec 2024 0 -26,384,000 -26,488,000 55,535,000 104,015,000 -48,480,000 -23,688,000
Dec 2023 0 -17,324,000 -16,490,000 17,562,000 39,804,000 -22,242,000 -13,510,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$825,735,000
Forward EPS
$-2.58

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $100.00 · spot: $124.39 · call volume: 107 · put volume: 18

Peers — same industry

TickerNameMarket CapLastDaily %
LQDA Liquidia Corp $5.10B $56.63 —
ERAS Erasca, Inc. $4.99B $14.22 —
PTCT PTC THERAPEUTICS, INC. $4.87B $58.33 —
COGT Cogent Biosciences, Inc. $4.83B $27.74 —
LGND LIGAND PHARMACEUTICALS INC $5.72B $286.94 —

News headlines (Yahoo Finance, 1h cache)

Veradermics to Present at the Jefferies Global Healthcare Conference in London
2026-11-12 21:30 · Yahoo
Veradermics: Q3 Earnings Snapshot
2026-11-10 22:49 · Yahoo
Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-11-10 12:30 · Yahoo
Veradermics stock rises on 12-month hair growth trial data
2026-11-09 18:04 · Yahoo
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
2026-11-08 23:00 · Yahoo
Veradermics (MANE) Late Stage Trial Narrative Keeps Undervalued View Alive
2026-11-06 15:13 · Yahoo
Connecticut Innovations Generates Record Breaking $51.4 Million in Venture Proceeds in Q1 FY27
2026-11-05 14:00 · Yahoo
Why This Hair Restoration Biotech's Shares Are Soaring
2026-10-25 13:20 · Yahoo
Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough
2026-10-22 10:24 · Yahoo
Veradermics’ stock up on male hair loss trial success
2026-10-19 17:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.